CI

At a glance

ClinicalIndex Comparison Record
Phase 3Unknown· 731 enrolled
Drug / intervention
cisplatin +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00632853
NCT00632853Phase 3Unknown

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide

Alliance for Clinical Trials in Oncology·interventional·Posted Mar 11, 2008·Updated Jun 12, 2023

In Brief

A Phase 3 clinical trial evaluating Standard Radiation Dose Therapy, cisplatin, and 3 other interventions for Lung Cancer. Targeting 731 participants across 934 sites in 4 countries.

Detailed Summary

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesIsrael, Puerto Rico, South Korea, United States

Timeline

Phase 3UnknownOverdue
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 11, 2008
Enrollment StartMar 1, 2008
Primary CompletionMar 2, 2022
TodayJul 2, 2026
Enrollment to primary: 14.0 yearsPosted 18.3 years ago

Interventions

Standard Radiation Dose Therapyradiation

45 Gy

cisplatindrug

IV

etoposidedrug

IV

High Radiation Dose Therapyradiation

70 Gy

carboplatindrug

IV